Lupus anticoagulant in patients with COVID-19

Int J Lab Hematol. 2021 Feb;43(1):e17-e18. doi: 10.1111/ijlh.13334. Epub 2020 Sep 11.

Authors

Ariella Tvito¹, Eli Ben-Chetrit², Frederic Shmuel Zimmerman³, Elad Asher⁴, Yigal Helviz³

Affiliations

¹ Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
² Infectious Diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
³ Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
⁴ Cardiology Department, Shaare Zedek Medical Center, Jerusalem, Israel.

PMID: 32915472
DOI: 10.1111/ijlh.13334

No abstract available

Keywords: COVID-19; anticoagulation; antiphospholipid antibodies; lupus anticoagulant; thromboembolic events.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Anticardiolipin / blood*
Antibodies, Antiphospholipid / blood*
C-Reactive Protein / analysis
COVID-19 / blood*
COVID-19 / epidemiology
COVID-19 / virology
Epidemics
Female
Fibrin Fibrinogen Degradation Products / analysis
Fibrinogen / analysis
Humans
Lupus Coagulation Inhibitor / blood*
Male
Middle Aged
SARS-CoV-2 / isolation & purification*
SARS-CoV-2 / physiology

Substances

Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Fibrin Fibrinogen Degradation Products
Lupus Coagulation Inhibitor
fibrin fragment D
Fibrinogen
C-Reactive Protein